DOP2017000270A - Composiciones farmacéuticas tópicas - Google Patents

Composiciones farmacéuticas tópicas

Info

Publication number
DOP2017000270A
DOP2017000270A DO2017000270A DO2017000270A DOP2017000270A DO P2017000270 A DOP2017000270 A DO P2017000270A DO 2017000270 A DO2017000270 A DO 2017000270A DO 2017000270 A DO2017000270 A DO 2017000270A DO P2017000270 A DOP2017000270 A DO P2017000270A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical compositions
patient
topical pharmaceutical
relates
oil phase
Prior art date
Application number
DO2017000270A
Other languages
English (en)
Inventor
Bedard Mary
D Lenn Jon
L Santos Leandro
D Sonti Sujatha
Roger Thomas Joey
E Whiteman Justin
Quinn Doherty Michael
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2017000270(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of DOP2017000270A publication Critical patent/DOP2017000270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas tópicas en emulsión, que comprenden una cantidad terapéuticamente eficaz de 3,5-dihidroxi-4-isopropil-trans-estilbeno o una de sus sales farmacéuticamente aceptables, una fase oleosa, una fase acuosa, un tensioactivo, y un antioxidante, y en donde la composición en emulsión es homogénea y/o el ingrediente activo se solubiliza en la fase oleosa. La invención se refiere también a métodos para tratar una afección o trastorno dermatológico en un paciente mediante la administración de las presentes composiciones a la piel del paciente.
DO2017000270A 2015-05-21 2017-11-21 Composiciones farmacéuticas tópicas DOP2017000270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
DOP2017000270A true DOP2017000270A (es) 2017-12-15

Family

ID=56081527

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000270A DOP2017000270A (es) 2015-05-21 2017-11-21 Composiciones farmacéuticas tópicas

Country Status (34)

Country Link
US (5) US10195160B2 (es)
EP (2) EP3297605B1 (es)
JP (3) JP6863904B2 (es)
KR (1) KR102669247B1 (es)
CN (2) CN114042041B (es)
AU (2) AU2016263161B2 (es)
BR (1) BR112017024934A8 (es)
CA (1) CA2986251A1 (es)
CL (1) CL2017002939A1 (es)
CO (1) CO2017011795A2 (es)
CR (1) CR20170528A (es)
DK (1) DK3297605T3 (es)
DO (1) DOP2017000270A (es)
EA (1) EA038624B1 (es)
ES (1) ES2914112T3 (es)
HK (1) HK1245074A1 (es)
HR (1) HRP20220670T1 (es)
HU (1) HUE059066T2 (es)
IL (2) IL255203B (es)
JO (1) JO3680B1 (es)
LT (1) LT3297605T (es)
MX (2) MX2017014804A (es)
PE (1) PE20180038A1 (es)
PH (1) PH12017502092A1 (es)
PL (1) PL3297605T3 (es)
PT (1) PT3297605T (es)
RS (1) RS63402B1 (es)
SG (1) SG11201708666RA (es)
SI (1) SI3297605T1 (es)
TW (1) TWI705831B (es)
UA (1) UA125500C2 (es)
UY (1) UY36682A (es)
WO (1) WO2016185428A1 (es)
ZA (1) ZA202007965B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114042041B (zh) * 2015-05-21 2023-08-22 德玛万科学有限责任公司 局部药物组合物
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CA3082115A1 (en) * 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
KR20220022115A (ko) * 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
US11807810B2 (en) 2019-06-26 2023-11-07 Locus Solutions Ipco, Llc Multi-functional compositions comprising concentrated acids for enhanced oil and gas recovery
WO2021014447A1 (en) * 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
WO2021059283A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4054526A4 (en) * 2019-11-06 2023-05-24 Sol-Gel Technologies Ltd. METHOD OF TREATMENT OF PALMÖBOT TEER KERATODERMA
US20230000786A1 (en) * 2019-11-24 2023-01-05 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
CA3183195A1 (en) * 2020-06-24 2021-12-30 Piyush Jain Topical pharmaceutical compositions
JP2024506953A (ja) * 2021-02-17 2024-02-15 ダーマバント、サイエンシーズ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Ｐｌａｑｕｅ乾癬、アトピー性皮膚炎、放射線性皮膚炎の治療におけるタピナロフの改善効果
US20220265750A1 (en) * 2021-02-25 2022-08-25 Alphyn Biologics, Llc Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
WO1995003695A1 (en) 1993-07-27 1995-02-09 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria xenorhabdus and photorhabdus spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
US6210693B1 (en) 1998-02-10 2001-04-03 Shiseido Company, Ltd. Oil-in-water type emulsified composition
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
WO1999059561A2 (en) 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
CA2393297C (en) 1999-12-06 2010-10-05 Welichem Biotech Inc. Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
EP1368306B1 (en) 2001-01-18 2013-01-16 Welichem Biotech Inc. Novel 1,2-diphenylethene derivatives for treatment of immune diseases
WO2003009807A2 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
WO2003077856A2 (en) * 2002-03-12 2003-09-25 Playtex Products, Inc. Lotion compositions
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
AP2006003784A0 (en) 2004-03-18 2006-10-31 Panacea Biotec Ltd Novel compositions for topical delivery
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
DE602005008635D1 (de) * 2004-10-19 2008-09-11 Boots Co Ltd Kosmetische zusammensetzungen
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
WO2009007785A2 (en) * 2006-11-14 2009-01-15 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9308239B2 (en) 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
PT2400951T (pt) * 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
MX2012010007A (es) * 2010-03-01 2012-10-01 Photocure Asa Composiciones cosmeticas.
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
EP3181121B1 (en) 2010-12-03 2020-10-28 EPI Health, LLC Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
MX349048B (es) 2011-06-27 2017-07-07 Galderma Res & Dev Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
ES2829637T3 (es) 2014-12-12 2021-06-01 Dermavant Sciences GmbH 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CN114042041B (zh) 2015-05-21 2023-08-22 德玛万科学有限责任公司 局部药物组合物
CA3082115A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof

Also Published As

Publication number Publication date
US20200101027A1 (en) 2020-04-02
HUE059066T2 (hu) 2022-10-28
IL255203A0 (en) 2017-12-31
CA2986251A1 (en) 2016-11-24
US20190192445A1 (en) 2019-06-27
ZA202007965B (en) 2022-12-21
US11458108B2 (en) 2022-10-04
JP2021105027A (ja) 2021-07-26
PL3297605T3 (pl) 2022-07-11
KR102669247B1 (ko) 2024-05-27
BR112017024934A2 (pt) 2018-07-31
CN114042041B (zh) 2023-08-22
US11622945B2 (en) 2023-04-11
DK3297605T3 (da) 2022-06-07
CR20170528A (es) 2018-01-22
WO2016185428A1 (en) 2016-11-24
US20160338973A1 (en) 2016-11-24
JP6863904B2 (ja) 2021-04-21
CL2017002939A1 (es) 2018-03-16
UY36682A (es) 2016-12-30
UA125500C2 (uk) 2022-04-13
HK1245074A1 (zh) 2018-08-24
HRP20220670T1 (hr) 2022-08-19
CN107666902B (zh) 2021-09-21
SG11201708666RA (en) 2017-12-28
EP4094752A1 (en) 2022-11-30
US10195160B2 (en) 2019-02-05
EP3297605A1 (en) 2018-03-28
BR112017024934A8 (pt) 2021-03-30
PE20180038A1 (es) 2018-01-09
AU2019203627A1 (en) 2019-06-13
IL255203B (en) 2021-05-31
PH12017502092A1 (en) 2018-05-07
AU2016263161B2 (en) 2019-02-28
US20190192446A1 (en) 2019-06-27
AU2016263161A1 (en) 2017-11-16
MX2017014804A (es) 2018-02-15
RS63402B1 (sr) 2022-08-31
AU2019203627B2 (en) 2020-12-24
MX2020012595A (es) 2021-02-09
EA038624B1 (ru) 2021-09-24
TW201705940A (zh) 2017-02-16
US11612573B2 (en) 2023-03-28
CN107666902A (zh) 2018-02-06
ES2914112T3 (es) 2022-06-07
JP2023113829A (ja) 2023-08-16
LT3297605T (lt) 2022-06-27
US20190151255A1 (en) 2019-05-23
JO3680B1 (ar) 2020-08-27
TWI705831B (zh) 2020-10-01
CO2017011795A2 (es) 2018-02-28
EA201792559A1 (ru) 2018-04-30
EP3297605B1 (en) 2022-05-04
PT3297605T (pt) 2022-05-30
US10426743B2 (en) 2019-10-01
JP2018515561A (ja) 2018-06-14
SI3297605T1 (sl) 2022-08-31
KR20180008490A (ko) 2018-01-24
IL282304A (en) 2021-05-31
CN114042041A (zh) 2022-02-15

Similar Documents

Publication Publication Date Title
DOP2017000270A (es) Composiciones farmacéuticas tópicas
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR117730A1 (es) Composición para relajación muscular
CL2019000625A1 (es) Combinación de agonistas de fxr.
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
CL2018003268A1 (es) Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel.
BR112015031835A8 (pt) agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético
BR112015019307A2 (pt) derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada
BR112014033088A2 (pt) composição para prevenção ou tratamento de colite compreendendo s-alil-l-cisteína como ingrediente ativo, e preparação médica compreendendo a mesma
BR112018007374A2 (pt) composição farmacêutica
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento
CL2018003269A1 (es) Ácidos carboxílicos para aplicación en la primera infancia.
AR108792A1 (es) Composiciones que comprenden timolol
BR112017021374A2 (pt) ácido pirrolidona carboxílico (pca) para uso oftálmico
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor